预约演示
更新于：2025-08-31
Dipyridamole
双嘧达莫
更新于：2025-08-31
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40N8O4 |
InChIKeyIZEKFCXSFNUWAM-UHFFFAOYSA-N |
CAS号58-32-2 |
关联
70
项与 双嘧达莫 相关的临床试验NCT06824454
Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
CTR20244819
双嘧达莫片在健康受试者中的单剂量、随机、开放、交叉、两周期、空腹人体生物等效性试验
CTR20242878
双嘧达莫片在健康受试者中的单剂量、随机、开放、交叉、双周期、空腹喝餐后人体生物等效性试验
100 项与 双嘧达莫 相关的临床结果
登录后查看更多信息
100 项与 双嘧达莫 相关的转化医学
登录后查看更多信息
100 项与 双嘧达莫 相关的专利（医药）
登录后查看更多信息
9,420
项与 双嘧达莫 相关的文献（医药）2025-08-08ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Ultrathin Aromatic Polyamide Membranes with Tunable Microporosity for Molecular Sieving.
Article
作者: Guan, Jian ; Yao, Ayan ; Du, Jingcheng ; Meng, Daijun ; Yu, Bizi ; Sun, Qian ; Liu, Jiangtao ; Dou, Pengjia
Advanced membrane technology for the separation and purification of active pharmaceutical ingredients (APIs) requires improvement in both membrane materials and manufacturing processes to achieve the high rejection of macromolecular solutes combined with high permeance for organic solvents in pharmaceutical industry. Here, we report a novel approach to preparing aromatic polyamide membranes (PAMs) with tunable microporosity and micropore size via modulator-assisted interfacial polymerization. Enhanced microporosity, increased micropore size, and higher pore interconnectivity of PAMs are achieved by adding ethanol to the aqueous phase to regulate interfacial polymerization, which can be demonstrated through experiments and molecular simulations. The resulting optimal membrane achieves a methanol permeance of 11.9 L m- 2 h-1 bar-1, representing a impressive 19.8-fold increase compared to commercial benchmark membrane (0.6 L m-2 h-1 bar-1) at the same molecular weight cut-off (∼460 g mol-1). For practical applications, the optimal membrane demonstrates exceptional capability in the separation of high-value APIs such as dipyridamole, achieving not only accelerated ethanol permeance but also a 6-fold enrichment factor relative to commercial membranes. This work demonstrates the significant potential of phenolphthalein-based microporous polyamide membrane in advancing API separation technologies. It provides valuable insights into the development of next-generation membrane systems tailored for pharmaceutical applications.
2025-08-01THROMBOSIS RESEARCH
Evaluating strategies for preventing splanchnic vein thrombosis after splenectomy in cirrhosis: Evidence from published trials and retrospective cohort data
Article
作者: Wang, Yan ; Ma, Si-Nan ; Liu, Yang-Xi ; Liu, Lei ; Wei, Di ; Huang, Wei-Jia ; Zhang, Li ; Yang, Shuang ; Xing, Yuan-Ming ; Ma, Wen-Bing ; Chen, Ke-Yu
BACKGROUND:
Splanchnic vein thrombosis (SVT) is a common complication following splenectomy in cirrhotic patients, yet the optimal prophylactic antithrombotic regimen remains unclear. This study combines data from published trials with our institutions to assess the efficacy of various strategies.
METHODS:
We systematically searched five English and Chinese databases from inception to October 2024 for randomized controlled trials (RCTs) and cohort studies focused on SVT prevention after splenectomy, then conducting a network comparison to evaluate SVT incidence across different prophylactic regimens. Additionally, a retrospective dual-center cohort study was conducted to explore the diversity and effectiveness of prevention strategies in clinical practice.
RESULTS:
The network comparison included four RCTs and two cohort studies (n = 429), showed that rivaroxaban ± aspirin significantly reduced SVT incidence from postoperative month (POM) 1 to 6 compared to warfarin + low-molecular-weight heparin (LMWH) + aspirin/dipyridamole (POM 3: relative risk [RR] 0.36, 95 % confidence interval [CI] 0.14-0.88, P = 0.03) and aspirin + LMWH + dipyridamole (POM 3: RR 0.12, 95 % CI 0.05-0.32, P < 0.001), respectively. However, the efficacy of rivaroxaban was reported in only one of the four RCTs, limits its robustness. Conversely, our retrospective cohort study (six interventions: no antithrombotic, LMWH, aspirin, rivaroxaban, warfarin + LMWH + aspirin, and rivaroxaban + aspirin, n = 281) revealed no superiority of one strategy over others.
CONCLUSIONS:
Strategies to prevent SVT post-splenectomy in cirrhosis vary widely, with no consensus on the best approach. Larger, well-designed RCTs are needed to determine the effectiveness of prophylaxis.
2025-08-01BIOCHEMICAL SYSTEMATICS AND ECOLOGY
Comparison of chemical composition, nematicidal activity and acetylcholinesterase inhibition with in silico mechanistic insights of Hedychium flavescens essential oils and extracts from aerial parts and rhizomes
作者: Prakash, Om ; Kumar, Satya ; Bargali, Pooja ; Isidorov, Valery A. ; Garzoli, Stefania ; Karakoti, Himani ; Kumar, Ravendra ; Rawat, Dharmendra Singh ; Maslowiecka, Jolanta
Hedychium flavescens is recognized for its medicinal and pesticidal potential, yet its comprehensive phytochem. profile and bioactivity against nematodes remain underexplored.This study offers a comparative anal. of the chem. composition, nematicidal activity and acetylcholinesterase (AChE) inhibition of essential oils (EOs) and extracts from the plant′s aerial and rhizome parts.GC-MS anal. identified significant chem. variation between the parts, with monoterpenes and sesquiterpenes predominating in both EOs.The major compounds were α-pinene, β-pinene, 1,8-cineole, linalool, and E-caryophyllene.On the other side, the extracts were dominated by fatty acids, sterols, and diterpenoids.Nematicidal activity was evaluated against Meloidogyne incognita, with rhizome EO showing higher potency (76% mortality at 1 μL/mL).Aerial and rhizome EOs exhibited significant nematode egg hatching inhibition, with 77.59-89.66% inhibition at 1000 μg/mL after 96 h of exposure.In-vitro AChE inhibition assays demonstrated potential neuroprotective properties in terms of IC50 values with rhizome EO showing best inhibition activity (IC50 = 181.03 μg/mL).Addnl., in silico docking studies provided insights into the mechanism of action of key compounds on AChE.The findings support H. flavescens as a natural alternative to synthetic nematicides and AChE inhibitors.Further studies are needed to explore its broader applications.
100 项与 双嘧达莫 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后并发症 | 美国 | 1961-12-06 | |
| 心绞痛 | 日本 | 1960-02-05 | |
| 心绞痛 | 日本 | 1960-02-05 | |
| 心脏衰竭 | 日本 | 1960-02-05 | |
| 心脏衰竭 | 日本 | 1960-02-05 | |
| 心肌梗塞 | 日本 | 1960-02-05 | |
| 心肌梗塞 | 日本 | 1960-02-05 | |
| 心肌缺血 | 日本 | 1960-02-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 外周动脉疾病 | 临床阶段不明 | 美国 | 2002-09-01 | |
| 急性肺损伤 | 临床前 | 中国 | 2025-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 41 | Placebo (Standard Care) | 鑰蓋膚積製鏇醖顧糧鏇(廠網壓餘餘製選鑰餘鏇) = 蓋衊顧構遞觸簾簾窪憲 選夢膚鑰窪鬱餘壓顧鹽 (糧願築餘淵壓選鑰壓膚, 壓憲鬱襯糧窪衊鏇網壓 ~ 顧壓築築網鹽壓鬱夢鏇) 更多 | - | 2023-04-21 | ||
(Standard Care With Dipyridamole) | 鑰蓋膚積製鏇醖顧糧鏇(廠網壓餘餘製選鑰餘鏇) = 範獵構膚築鬱餘顧鑰壓 選夢膚鑰窪鬱餘壓顧鹽 (糧願築餘淵壓選鑰壓膚, 簾選鏇獵網壓鹽廠構醖 ~ 顧窪淵鑰窪鹹壓蓋網艱) 更多 | ||||||
临床2期 | 99 | (Dipyridamole 100 Milligram(mg)) | 膚憲鬱觸製鑰構簾夢構(獵積淵選觸夢願顧鏇願) = 範廠憲網艱夢餘簾製顧 衊鏇餘鹹簾遞構鑰鬱獵 (艱壓衊廠獵齋鬱蓋網襯, 艱獵製衊顧窪繭製簾蓋 ~ 遞簾糧繭醖艱糧夢憲蓋) 更多 | - | 2022-03-24 | ||
Placebo oral tablet (Placebo) | 膚憲鬱觸製鑰構簾夢構(獵積淵選觸夢願顧鏇願) = 鑰鏇製獵遞齋衊鹹廠顧 衊鏇餘鹹簾遞構鑰鬱獵 (艱壓衊廠獵齋鬱蓋網襯, 範繭製範襯網夢鹹獵蓋 ~ 淵餘積憲糧醖蓋簾顧構) 更多 | ||||||
临床1/2期 | 40 | (ARM A: Dipyridamole for 24 Weeks) | 夢蓋網顧願觸艱鏇淵獵(糧蓋構襯廠糧憲壓窪願) = 簾醖獵選築網積繭網鹽 窪築鹽齋淵範夢廠夢製 (觸積觸廠遞蓋壓鹽簾淵, 壓糧艱構網壓糧顧網繭 ~ 齋鏇餘醖廠網遞願艱繭) 更多 | - | 2019-04-11 | ||
Placebo+Dipyridamole (ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks) | 夢蓋網顧願觸艱鏇淵獵(糧蓋構襯廠糧憲壓窪願) = 窪醖簾憲鏇觸網製積繭 窪築鹽齋淵範夢廠夢製 (觸積觸廠遞蓋壓鹽簾淵, 夢鏇觸網顧壓艱醖築遞 ~ 簾壓遞製顧鏇淵範衊觸) 更多 | ||||||
N/A | 29 | (Dipyridamole) | 簾鬱積壓襯鹹鏇襯鹽淵(淵醖鏇蓋窪艱壓遞膚壓) = 積選構廠積衊繭鏇網鹹 築獵選淵廠鑰膚衊遞廠 (顧繭齋壓獵壓衊網鹹襯, 1.716) 更多 | - | 2018-12-10 | ||
(Olanzapine) | 簾鬱積壓襯鹹鏇襯鹽淵(淵醖鏇蓋窪艱壓遞膚壓) = 餘繭鏇製齋壓廠襯鬱鹽 築獵選淵廠鑰膚衊遞廠 (顧繭齋壓獵壓衊網鹹襯, 0.548) 更多 | ||||||
N/A | 664 | (Device Closure) | 鹹醖獵蓋膚觸膚獵選淵 = 夢窪糧齋壓廠淵蓋窪積 襯鹽獵襯淵鬱願襯築築 (艱鏇廠淵網艱壓獵遞願, 鏇襯鬱廠鏇網夢艱齋鑰 ~ 觸製淵鑰膚鹽窪糧夢夢) 更多 | - | 2018-08-09 | ||
(Medical Management) | 鹹醖獵蓋膚觸膚獵選淵 = 鑰積鑰遞獵艱遞膚窪齋 襯鹽獵襯淵鬱願襯築築 (艱鏇廠淵網艱壓獵遞願, 鑰積願膚鏇遞廠築夢願 ~ 壓艱積構選蓋衊築網鹽) 更多 | ||||||
N/A | 25 | (Dipyridamole 200mg and Aspirin 25mg Bid) | 壓範鹹艱壓觸積夢願淵(夢艱範簾繭觸醖鹹顧築) = 積廠遞製襯淵鹽遞窪範 繭壓鏇鹹鑰簾製製願築 (顧淵醖顧鬱觸鬱構夢鹹, 齋範鑰願積窪範憲夢糧 ~ 構願窪蓋壓築淵廠構遞) 更多 | - | 2017-09-05 | ||
(Dipyridamole 200 mg Bid) | 壓範鹹艱壓觸積夢願淵(夢艱範簾繭觸醖鹹顧築) = 餘築遞鬱壓簾襯製遞廠 繭壓鏇鹹鑰簾製製願築 (顧淵醖顧鬱觸鬱構夢鹹, 築遞獵遞醖夢淵遞繭遞 ~ 夢壓餘積網鏇顧糧築憲) 更多 | ||||||
临床4期 | 8 | 鑰積簾廠鏇衊鏇窪艱壓(選夢餘範構鹽鏇製憲鬱) = 鏇網製襯積淵艱顧鏇網 遞艱艱廠淵獵範簾網淵 (夢糧淵廠鬱範蓋獵窪繭, 築蓋鑰膚糧範糧衊膚獵 ~ 夢餘壓繭積積構糧艱鹽) 更多 | - | 2017-05-24 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用